 Ann Kulungowski
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 9 | 2025 | 50 | 3.870 |
Why?
| | Lymphatic Abnormalities | 3 | 2020 | 21 | 1.590 |
Why?
| | Hemangioma | 7 | 2025 | 45 | 1.230 |
Why?
| | Sclerotherapy | 2 | 2018 | 20 | 1.070 |
Why?
| | Pneumatosis Cystoides Intestinalis | 2 | 2024 | 22 | 0.960 |
Why?
| | Secondary Prevention | 2 | 2018 | 241 | 0.960 |
Why?
| | Wounds, Penetrating | 2 | 2023 | 73 | 0.860 |
Why?
| | Surgical Wound | 1 | 2023 | 27 | 0.770 |
Why?
| | Chylous Ascites | 1 | 2022 | 5 | 0.760 |
Why?
| | Liver Neoplasms | 7 | 2025 | 755 | 0.760 |
Why?
| | Chylothorax | 1 | 2022 | 20 | 0.750 |
Why?
| | Neutropenia | 1 | 2023 | 152 | 0.750 |
Why?
| | Respiration Disorders | 1 | 2022 | 79 | 0.720 |
Why?
| | Surgeons | 2 | 2025 | 336 | 0.710 |
Why?
| | Wounds, Nonpenetrating | 3 | 2019 | 311 | 0.680 |
Why?
| | Intestines | 2 | 2022 | 355 | 0.630 |
Why?
| | Surgery Department, Hospital | 2 | 2016 | 23 | 0.610 |
Why?
| | Hypovolemia | 1 | 2019 | 12 | 0.600 |
Why?
| | Infant | 24 | 2026 | 9908 | 0.600 |
Why?
| | Pediatric Emergency Medicine | 1 | 2019 | 24 | 0.600 |
Why?
| | Vertebral Artery | 1 | 2019 | 27 | 0.600 |
Why?
| | Carotid Artery Injuries | 1 | 2019 | 40 | 0.590 |
Why?
| | Doxycycline | 1 | 2018 | 60 | 0.560 |
Why?
| | Medical Errors | 1 | 2019 | 121 | 0.540 |
Why?
| | Child | 25 | 2026 | 22562 | 0.530 |
Why?
| | Craniocerebral Trauma | 1 | 2019 | 176 | 0.510 |
Why?
| | Sclerosing Solutions | 1 | 2016 | 10 | 0.500 |
Why?
| | Hospital Rapid Response Team | 1 | 2016 | 21 | 0.500 |
Why?
| | Infant, Newborn | 16 | 2025 | 6324 | 0.500 |
Why?
| | Veins | 1 | 2016 | 70 | 0.480 |
Why?
| | Bevacizumab | 1 | 2016 | 135 | 0.470 |
Why?
| | Patient Safety | 1 | 2019 | 339 | 0.460 |
Why?
| | Interferon-alpha | 1 | 2016 | 196 | 0.450 |
Why?
| | Ileal Diseases | 1 | 2014 | 13 | 0.440 |
Why?
| | Gastrostomy | 2 | 2026 | 128 | 0.420 |
Why?
| | Hospitals, Pediatric | 2 | 2016 | 551 | 0.400 |
Why?
| | Rectum | 2 | 2015 | 187 | 0.400 |
Why?
| | Child Abuse | 1 | 2019 | 549 | 0.390 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2927 | 0.380 |
Why?
| | Child, Preschool | 17 | 2026 | 11634 | 0.380 |
Why?
| | Receptors, Somatotropin | 1 | 2012 | 10 | 0.380 |
Why?
| | Genital Neoplasms, Male | 1 | 2011 | 5 | 0.350 |
Why?
| | Blood Transfusion | 4 | 2022 | 397 | 0.350 |
Why?
| | Genitalia, Male | 1 | 2011 | 11 | 0.350 |
Why?
| | Patients | 2 | 2023 | 180 | 0.350 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 18 | 0.350 |
Why?
| | Registries | 4 | 2025 | 2227 | 0.350 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 639 | 0.340 |
Why?
| | Neoplasms | 2 | 2024 | 2761 | 0.340 |
Why?
| | Disease Management | 1 | 2015 | 641 | 0.340 |
Why?
| | Receptors, Androgen | 1 | 2012 | 154 | 0.340 |
Why?
| | Crohn Disease | 1 | 2014 | 256 | 0.330 |
Why?
| | Retrospective Studies | 19 | 2026 | 16626 | 0.330 |
Why?
| | Blood Vessels | 1 | 2012 | 175 | 0.330 |
Why?
| | Humans | 43 | 2026 | 142526 | 0.330 |
Why?
| | Adolescent | 17 | 2026 | 22326 | 0.330 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 341 | 0.320 |
Why?
| | Mesenteric Veins | 1 | 2010 | 23 | 0.320 |
Why?
| | HELLP Syndrome | 1 | 2009 | 6 | 0.320 |
Why?
| | Hemangioendothelioma | 2 | 2025 | 13 | 0.310 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 245 | 0.310 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 412 | 0.300 |
Why?
| | Portal Vein | 1 | 2010 | 111 | 0.300 |
Why?
| | Venous Thrombosis | 1 | 2010 | 194 | 0.280 |
Why?
| | Laparoscopy | 2 | 2026 | 471 | 0.270 |
Why?
| | Skin Neoplasms | 3 | 2025 | 856 | 0.270 |
Why?
| | Suture Techniques | 2 | 2026 | 129 | 0.270 |
Why?
| | Bone Transplantation | 3 | 2012 | 90 | 0.250 |
Why?
| | Gastropexy | 1 | 2026 | 4 | 0.240 |
Why?
| | Sutures | 1 | 2025 | 60 | 0.220 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2025 | 8 | 0.220 |
Why?
| | Anticoagulants | 1 | 2010 | 725 | 0.220 |
Why?
| | Hemorrhage | 1 | 2009 | 798 | 0.210 |
Why?
| | Sarcoma, Kaposi | 1 | 2025 | 83 | 0.210 |
Why?
| | Anti-Bacterial Agents | 3 | 2024 | 1881 | 0.210 |
Why?
| | Recurrence | 2 | 2018 | 1111 | 0.210 |
Why?
| | Specialties, Surgical | 1 | 2025 | 80 | 0.210 |
Why?
| | Phlebography | 2 | 2016 | 39 | 0.210 |
Why?
| | Male | 26 | 2026 | 70910 | 0.210 |
Why?
| | Physicians, Women | 1 | 2025 | 87 | 0.200 |
Why?
| | Treatment Outcome | 8 | 2024 | 11298 | 0.200 |
Why?
| | Hepatoblastoma | 1 | 2024 | 47 | 0.200 |
Why?
| | Postoperative Complications | 2 | 2026 | 2862 | 0.190 |
Why?
| | Craniotomy | 3 | 2012 | 80 | 0.190 |
Why?
| | Radiography, Interventional | 1 | 2024 | 129 | 0.190 |
Why?
| | Lymphedema | 2 | 2014 | 24 | 0.190 |
Why?
| | Ascites | 1 | 2022 | 49 | 0.190 |
Why?
| | Mosaicism | 1 | 2022 | 74 | 0.180 |
Why?
| | Noonan Syndrome | 1 | 2022 | 14 | 0.180 |
Why?
| | Female | 23 | 2026 | 76624 | 0.180 |
Why?
| | Parietal Bone | 2 | 2012 | 9 | 0.180 |
Why?
| | Frontal Bone | 2 | 2012 | 21 | 0.180 |
Why?
| | Radiologists | 1 | 2022 | 62 | 0.180 |
Why?
| | Drainage | 1 | 2022 | 177 | 0.170 |
Why?
| | Rabbits | 4 | 2016 | 664 | 0.170 |
Why?
| | Incidence | 4 | 2022 | 2826 | 0.170 |
Why?
| | Congenital Abnormalities | 1 | 2022 | 107 | 0.170 |
Why?
| | Professional Role | 1 | 2022 | 167 | 0.170 |
Why?
| | Risk Factors | 6 | 2024 | 10593 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2024 | 360 | 0.160 |
Why?
| | Skin | 1 | 2025 | 769 | 0.160 |
Why?
| | Neovascularization, Pathologic | 2 | 2011 | 295 | 0.150 |
Why?
| | Surgical Wound Infection | 1 | 2023 | 325 | 0.150 |
Why?
| | Endovascular Procedures | 1 | 2024 | 372 | 0.150 |
Why?
| | Abdominal Cavity | 1 | 2018 | 6 | 0.150 |
Why?
| | Duodenostomy | 1 | 2018 | 3 | 0.140 |
Why?
| | Duodenal Obstruction | 1 | 2018 | 5 | 0.140 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2018 | 20 | 0.140 |
Why?
| | Duodenum | 1 | 2018 | 77 | 0.140 |
Why?
| | Thoracotomy | 1 | 2018 | 81 | 0.140 |
Why?
| | Thoracic Injuries | 1 | 2018 | 69 | 0.130 |
Why?
| | Shock, Hemorrhagic | 1 | 2019 | 198 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2024 | 686 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5270 | 0.130 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 157 | 0.130 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2016 | 16 | 0.130 |
Why?
| | Electronic Health Records | 1 | 2025 | 1144 | 0.130 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 59 | 0.120 |
Why?
| | Hemangioma, Capillary | 1 | 2015 | 14 | 0.120 |
Why?
| | Hypotension | 1 | 2016 | 126 | 0.120 |
Why?
| | Shock | 1 | 2016 | 105 | 0.120 |
Why?
| | Risk Assessment | 3 | 2015 | 3562 | 0.110 |
Why?
| | Drug Carriers | 1 | 2016 | 127 | 0.110 |
Why?
| | Pyloric Stenosis, Hypertrophic | 1 | 2015 | 10 | 0.110 |
Why?
| | Catheters, Indwelling | 1 | 2015 | 92 | 0.110 |
Why?
| | Angiogenesis Inhibitors | 1 | 2016 | 230 | 0.110 |
Why?
| | Genital Diseases, Male | 1 | 2014 | 17 | 0.110 |
Why?
| | Penis | 1 | 2014 | 34 | 0.110 |
Why?
| | Hirschsprung Disease | 1 | 2015 | 85 | 0.110 |
Why?
| | Urologic Surgical Procedures, Male | 1 | 2014 | 32 | 0.110 |
Why?
| | Scrotum | 1 | 2014 | 26 | 0.110 |
Why?
| | Peritoneal Dialysis | 1 | 2015 | 97 | 0.110 |
Why?
| | Wounds and Injuries | 1 | 2022 | 930 | 0.100 |
Why?
| | Neonatal Screening | 1 | 2015 | 174 | 0.100 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 109 | 0.100 |
Why?
| | Gastroenterology | 1 | 2015 | 186 | 0.100 |
Why?
| | Postoperative Care | 1 | 2015 | 281 | 0.100 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1364 | 0.100 |
Why?
| | Global Health | 1 | 2015 | 387 | 0.090 |
Why?
| | Arteriovenous Malformations | 1 | 2012 | 29 | 0.090 |
Why?
| | Databases, Factual | 2 | 2024 | 1458 | 0.090 |
Why?
| | Bone Resorption | 1 | 2012 | 84 | 0.090 |
Why?
| | Lipomatosis | 1 | 2011 | 5 | 0.090 |
Why?
| | Hamartoma | 1 | 2012 | 28 | 0.090 |
Why?
| | Cheek | 1 | 2011 | 17 | 0.090 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 270 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2053 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 62 | 0.090 |
Why?
| | alpha-Fetoproteins | 1 | 2011 | 40 | 0.090 |
Why?
| | Prospective Studies | 3 | 2012 | 7862 | 0.090 |
Why?
| | Young Adult | 6 | 2015 | 13878 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2167 | 0.080 |
Why?
| | Biomarkers | 2 | 2012 | 4207 | 0.080 |
Why?
| | Rare Diseases | 1 | 2011 | 113 | 0.080 |
Why?
| | Ligation | 1 | 2010 | 93 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5994 | 0.080 |
Why?
| | Skull | 1 | 2010 | 151 | 0.080 |
Why?
| | Prostheses and Implants | 1 | 2010 | 145 | 0.070 |
Why?
| | Length of Stay | 1 | 2015 | 1273 | 0.070 |
Why?
| | Osteogenesis | 1 | 2010 | 199 | 0.070 |
Why?
| | United States | 2 | 2024 | 15447 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1247 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1727 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2016 | 4483 | 0.070 |
Why?
| | Pediatrics | 1 | 2015 | 1110 | 0.070 |
Why?
| | Colorado | 1 | 2016 | 4638 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2251 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3776 | 0.060 |
Why?
| | Cellulitis | 1 | 2025 | 55 | 0.060 |
Why?
| | Adult | 4 | 2012 | 39715 | 0.050 |
Why?
| | Massachusetts | 2 | 2014 | 179 | 0.050 |
Why?
| | Vascular System Injuries | 1 | 2024 | 77 | 0.050 |
Why?
| | Age Factors | 2 | 2024 | 3316 | 0.050 |
Why?
| | Liver | 1 | 2011 | 1848 | 0.050 |
Why?
| | Prognosis | 1 | 2011 | 4112 | 0.050 |
Why?
| | Splenectomy | 1 | 2022 | 61 | 0.050 |
Why?
| | Perioperative Period | 1 | 2022 | 70 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 130 | 0.040 |
Why?
| | Esophageal Atresia | 1 | 2022 | 27 | 0.040 |
Why?
| | Tracheoesophageal Fistula | 1 | 2022 | 34 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 251 | 0.040 |
Why?
| | X-Ray Microtomography | 2 | 2012 | 103 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2022 | 124 | 0.040 |
Why?
| | Pyridones | 1 | 2022 | 194 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 432 | 0.040 |
Why?
| | Survival Rate | 2 | 2015 | 1995 | 0.040 |
Why?
| | Spleen | 1 | 2022 | 515 | 0.040 |
Why?
| | Animals | 4 | 2016 | 37697 | 0.040 |
Why?
| | Medicaid | 1 | 2024 | 457 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 885 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2024 | 1319 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2074 | 0.040 |
Why?
| | Mutation | 2 | 2022 | 4024 | 0.040 |
Why?
| | Heart Diseases | 1 | 2022 | 339 | 0.040 |
Why?
| | Operative Time | 1 | 2018 | 162 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2018 | 159 | 0.030 |
Why?
| | Pregnancy | 1 | 2009 | 7113 | 0.030 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 32 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2831 | 0.030 |
Why?
| | Middle Aged | 3 | 2014 | 35049 | 0.030 |
Why?
| | Dialysis Solutions | 1 | 2015 | 22 | 0.030 |
Why?
| | Resuscitation | 1 | 2018 | 298 | 0.030 |
Why?
| | Peritonitis | 1 | 2015 | 83 | 0.030 |
Why?
| | Anemia | 1 | 2016 | 175 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1977 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 143 | 0.030 |
Why?
| | Constipation | 1 | 2015 | 96 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2016 | 208 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2016 | 573 | 0.030 |
Why?
| | Heart Arrest | 1 | 2018 | 398 | 0.030 |
Why?
| | Needs Assessment | 1 | 2016 | 391 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 310 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 274 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 288 | 0.020 |
Why?
| | Morbidity | 1 | 2014 | 321 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2015 | 213 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 914 | 0.020 |
Why?
| | Gestational Age | 1 | 2015 | 961 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1081 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1508 | 0.020 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2011 | 20 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 58 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 381 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 83 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2014 | 1404 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2011 | 85 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 71 | 0.020 |
Why?
| | Osseointegration | 1 | 2011 | 71 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 138 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2102 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1678 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2081 | 0.020 |
Why?
| | Random Allocation | 1 | 2010 | 370 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 985 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 404 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 633 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 807 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 293 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 857 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 547 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 829 | 0.020 |
Why?
| | Cohort Studies | 1 | 2015 | 5858 | 0.010 |
Why?
| | Time Factors | 1 | 2015 | 7006 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2608 | 0.010 |
Why?
| | Aged | 1 | 2014 | 25117 | 0.010 |
Why?
|
|
Kulungowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|